[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ich---intracerebral-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ich---intracerebral-hemorrhage":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,75,97,128,157,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100554860","phase-2-effect-of-cilostazol-in-promoting-hematoma-clearance-after-intracerebral-hemorrhage-100554860",false,"NCT06504576","Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage","Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage: A Phase-II Open Label Study","EPOCH","Inclusion criteria:\n\n1. Adult patients (at least 20 years old, up to 80 years old)\n2. ICH located in the thalamus or basal ganglia.\n3. ICH score less than 3 (hematoma volume not greater than 15 ml) and was admitted within 24 hours since onset.\n4. The patient or his\u002Fher legal representative agrees to join this trial and accept the arrangements of tests within this trial.\n5. Patients with normal bone marrow and hematopoiesis (Red blood cell count, white blood cell count, platelet count within reference value).\n6. Patients with normal liver function (Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Gamma-glutamyl transferase (γ-GT) within reference value)\n7. Patients with normal renal function (Blood urea nitrogen (BUN), creatinine and estimated glomerular filtration rate (eGFR) within reference value)\n8. Patients with normal coagulation function (Platelet count, prothrombin time (PT), activate partial thromboplastin time (aPTT), international normalized ratio (INR) within reference value)\n\nExclusion criteria:\n\n1. Image studies conducted after intracerebral incidence and before enrollment showing higher bleeding risks such as spot sign in computed tomography angiography, new intraventricular hemorrhage (IVH), IVH expansion, irregular hematoma border, heterogenous hematoma component or hematoma expansion.\n2. Intracerebral hemorrhage located in the cerebral area, below the cerebellar tentorium or ICH score greater than 3 (not including 3).\n3. Surgical intevention such as decompressive craniotomy or hematoma evacuation was suggested after evaluation by neurosurgeon.\n4. Patients with history of brain trauma, structural brain disease, metabolic brain disease, neuroinflammatory disease or brain neoplasms.\n5. Patients that cannot tolerate image studies, including but not limited to those that cannot cooperate, affecting image quality due to agitation, presenting with unstable hemodynamics, installed with pacemakers incompatible with magnetic resonance imaging (MRI), has brain aneurysm clips or clasutorphobic.\n6. Patients with medical contraindications to MRI contrast medium, including chronic renal failure (Creatinine clearance rate less than 30ml\u002Fmin).\n7. Patients currently pregnant or expecting pregnancy or breastfeeding in six months.\n8. Patients taking oral anti-platelet medication (aspirin, clopidogrel, ticagrelor, cilostzaol) or anti-coagulant (warfarin, dabigatran, rivaroxaban, apixaban, edoxaban) when ICH occurred.\n9. Patients with medical contraindications to cilostazol, including heart failure with any severity, any coagulopathy, ventricular tachycardia, ventricular fibrillation, mulitfocal ventricular arrhythmia, severe tachycardic arrhythmia, unstable angina, myocardial infarction within six months, has history of receiving percutaneous coronary intervention, active pathological bleeding and severe hepatorenal insufficiency.\n10. Patients with poor blood pressure control (defined as systolic blood pressure greater than 160 mmHg under anti-hypertensive medication).\n11. Patients with unstable neurological conditions (defined as increase in National Institute of Health Stroke Scale (NIHSS) greater than 4 or newly occurred conscious change during admission).\n12. Patients with life expectancy less than three months.\n13. Patients with known allergy to any of the ingredient of the trial medication, and deemed unsuitable for enrollment of the study by the trial host.\n14. Patient or legal guardian of the patient refuses to be enrolled within the study.","ALL","20 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Intracerebral hemorrhage (ICH) is a dangerous form of stroke with high mortality rate. Other than evacuating the hematoma with surgical procedures, there is no current effective internal medicine treatment. Currently, there are many novel internal medicine treatment under development, one of which is the promotion of endogenous hematoma clearance. Our team recently found out that the meningeal lymphatic system plays an important role in clearing hematoma post-ICH, meaning that promoting the drainage function of the meningeal lymphatic system may have a certain level of help for improving the prognosis of ICH.\n\nCilostazol is an anti-PDE3 type antiplatelet agent with the function of preventing peripheral arterial occlusion disease and stroke. Cilostazol has been proven to promote lymphatic endothelial cell proliferation and the drainage function of the lymphatic system. Our animal research points out that Cilostazol speeds up hematoma clearance post-ICH and generates neuroprotective effects, thereby improving prognosis and providing a new internal medicine treatment for ICH.\n\nDue to the fact that there is no clinical trial looking into the hematoma resorption effect of Cilostazol in ICH patients, this trials aims to understand the safety and hematoma resorption efficacy of Cilostazol in acute ICH patients. Investigators estimate to enroll 100 patients in National Taiwan University Hospital (NTUH) within 3 years. The patients would be randomized into two groups, one receiving Cilostazol (two weeks, 50mg BID) and conventional treatment, and the other group receiving only conventional treatment. Investigators will assess the patients' neurological outcome and functional aspects (NIHSS, modified Rankin Scale) two weeks \u002F one month \u002F three months after ICH. Investigators will also use MRI to measure hematoma size to evaluate hematoma resorption (primary endpoint and safety endpoint). MRI will also be used to measure the drainage effect of the meningeal lymphatics.",[28],"ICH - Intracerebral Hemorrhage",[30,31,32,33],"intracerebral hemorrhage","cilostazol","meningeal lymphatic vessel","DCE-MRI","RECRUITING","2026-03-05",{"date":37,"type":38},"2026-03-09","ACTUAL",{"date":40,"type":38},"2025-06-16",{"date":42,"type":22},"2027-05-01",{"name":44,"class":45},"National Taiwan University Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100561251","phase-3-colchicine-for-the-reduction-of-dependency-and-vascular-events-after-an-acute-intracerebral-hemorrhage-100561251","NCT06587737","Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage","A Double-blind, Randomized, Placebo-controlled, Phase III Study for Reducing Dependency and Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous Intracerebral Hemorrhage and Established, or Risk Factors for, Atherosclerosis","CoVasc-ICH2","Inclusion Criteria:\n\nAdult patients presenting with spontaneous intraparenchymal hemorrhage within 72 hours of symptom onset and qualifying for at least one of the following categories:\n\ni. history of symptomatic coronary, peripheral and\u002For carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical\u002Fintracranial atherosclerotic disease causing any degree of stenosis\u002Focclusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL\u002Fmin), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease).\n\nExclusion Criteria:\n\n* secondary causes of ICH (such as trauma, macrovascular anomalies, neoplasms or bleeding diathesis)\n* ICH volume more than 60ml in the last imaging scan prior to consent\n* Glasgow Coma Scale (GCS) score less than 7 or being intubated at the time of consent\n* inflammatory bowel disease or chronic diarrhea\n* cirrhosis or severe hepatic dysfunction\n* renal insufficiency (eGFR\\\u003C15mL\u002Fmin)\n* concurrent or planned treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir\u002Fritonavir, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir\u002Fritonavir) or P-gp inhibitors (cyclosporine, ranolazine)\n* pregnancy or breast-feeding\n* known allergy or sensitivity to colchicine\n* a strong indication for colchicine where assignment to placebo is deemed unacceptable\n* estimated life expectancy less than 6 months at the time of enrollment, and\n* inability to adhere to study procedures","18 Years",{"count":57,"type":22},1125,[59],"PHASE3","Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant periods after hemorrhage. These findings highlight the need for novel treatments that modify the high risk for major vascular events and functional outcomes in ICH survivors.\n\nThe objective of CoVasc-ICH 2 is to demonstrate that oral colchicine 0.5 mg daily is superior to placebo for improving the outcomes of ICH survivors with evidence or risk factors for atherosclerosis, when started within 72 hours from ICH onset.",[62,28,63,64],"Colchicine","Stroke","Dependence","NOT_YET_RECRUITING","2026-02-23",{"date":68,"type":38},"2026-02-25",{"date":70,"type":22},"2026-05-30",{"date":72,"type":22},"2028-10-30",{"name":74,"class":45},"Population Health Research Institute",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":5},"100617257","safety-and-effectiveness-of-catheter-ablation-for-atrial-fibrillation-with-intracerebral-hemorrhage-safer-af-100617257","NCT07316270","SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracerebral Hemorrhage (SAFER-AF)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Between 14 Days and 12 Months After Spontaneous Intracerebral Hemorrhage\n3. Able to Access Intracerebral Hemorrhage Imaging Data\n4. ECG indicating the presence of atrial fibrillation\n5. CHA₂DS₂-VA Score ≥ 2\n6. Willing to undergo randomization and able to complete follow-up as required\n\nExclusion Criteria:\n\n1. Atrial fibrillation secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.)\n2. Fully dependent (modified Rankin Scale \\[mRS\\] score \\> 4)\n3. Uncontrolled hypertension (systolic blood pressure \\> 160 mmHg)\n4. Presence of uncontrolled active bleeding\n5. Presence of active infection requiring antibiotic treatment\n6. End-stage renal failure or receiving dialysis treatment\n7. Presence of liver failure\n8. Untreated coronary artery disease with indication for revascularization\n9. Presence of intracardiac masses, thrombi, etc., as evaluated by transthoracic echocardiography or transesophageal echocardiography\n10. Expected life expectancy \\\u003C 1 year (e.g., advanced malignant tumors, etc.)\n11. Pregnant, lactating, or women planning to become pregnant\n12. Presence of psychological or psychiatric disorders that prevent understanding or cooperation with the study\n13. Other conditions deemed unsuitable for participation in the study by the investigators",{"count":82,"type":22},646,[84],"NA","SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracerebral hemorrhage.",[87,28],"AF - Atrial Fibrillation","2025-12-30",{"date":90,"type":38},"2026-01-05",{"date":92,"type":22},"2026-01",{"date":94,"type":22},"2030-01",{"name":96,"class":45},"Beijing Anzhen Hospital",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100605426","phase-2-synergistic-minimally-invasive-surgery-and-deferoxamine-in-ich-100605426","NCT07162363","Synergistic Minimally Invasive Surgery and Deferoxamine in ICH","Synergistic Intervention of Minimally Invasive Surgery and Deferoxamine in Intracerebral Hemorrhage (SMAD)","SMAD","Inclusion Criteria:\n\nParticipants must meet all the following criteria:\n\n1. Age ≥ 18 and ≤ 80 years\n2. Spontaneous supratentorial ICH confirmed by CT or CTA, with hematoma volume:\n\n   * ≥30 mL on initial diagnostic CT, OR\n   * ≥25 mL on stability CT performed ≥6 hours after diagnostic CT,\n\n     1. Clot growth must be less than 5 mL between scans to be eligible\n     2. A second stability scan at least 12 hours later is allowed if clot expanded \\>5 mL\n3. NIHSS score ≥ 6 at enrollment\n4. Glasgow Coma Scale (GCS) score ≥5 and ≤14 at screening\n5. Symptoms onset ≤ 24 hours before diagnostic CT\n\n   * Use \"last known well\" for wake-up strokes\n   * Unknown onset is exclusionary\n6. SBP \\\u003C 180 mm Hg sustained for at least 6 hours prior to randomization\n7. Randomization must occur between 12 and 24 hours from initial diagnostic CT done at UIC or in case of transfers, at other institutions.\n8. Functionally independent pre-ICH, defined as mRS 0-1. Pre-ICH functional status will be determined from medical records and structured interviews with the patient or a reliable caregiver, with ambiguous cases adjudicated by the site PI. Patients with mRS 0-1 are considered functionally independent, able to perform all usual activities without assistance.\n9. Written informed consent obtained from patient or legal representative\n\nExclusion Criteria:\n\n1. Infratentorial hemorrhage (e.g., brainstem or cerebellar hematoma).\n2. Hemorrhage due to secondary causes: trauma, AVM, aneurysm, Moyamoya disease, hemorrhagic conversion of ischemic stroke, tumor, or vascular anomaly (diagnosed on imaging).\n3. Recurrent ICH within the past year.\n4. Intraventricular hemorrhage (IVH) requiring surgical treatment for trapped ventricle or mass effects (e.g., endoscopic evacuation). EVD is permitted.\n5. Evidence of irreversible impaired brainstem function (e.g., bilateral fixed dilated pupils, decerebrate posturing).\n6. Glasgow Coma Scale (GCS) ≤ 4 at screening, indicating extremely poor neurologic prognosis. NIHSS item 1a = 3, indicating comatose status (unresponsive to verbal or painful stimulation).\n7. Thalamic ICH with midbrain extension and third nerve palsy.\n8. Clinical indication for emergent surgical hematoma evacuation, as determined by treating neurosurgeons.\n9. NIHSS score \\\u003C 6 (too mild to benefit).\n10. Expected withdrawal of care or death within 72 hours.\n11. Prior enrollment in the study.\n12. Creatinine ≥ 2.0 mg\u002FdL or evidence of severe renal impairment.\n13. Active hepatic failure or severe hepatic disease.\n14. Pregnancy or breastfeeding.\n15. Severe iron deficiency anemia (Hgb \\\u003C 8 g\u002FdL or ferritin \\\u003C15 ng\u002FmL).\n16. Active systemic infection (e.g., sepsis, subacute bacterial endocarditis).\n17. Active internal bleeding (GI, GU, retroperitoneal, pulmonary).\n18. History of mechanical heart valve (bioprosthetic valves allowed).\n19. Known left atrial\u002Fventricular thrombus or high embolic risk (e.g., mitral stenosis + AFib).\n20. Any coagulopathy:\n\n    * Platelet count \\\u003C100,000\n    * INR \\> 1.4 not correctable within 6 hours\n    * Use of NOACs (apixaban, rivaroxaban, dabigatran) or LMWH at presentation\n21. Long-term anticoagulation that cannot be stopped safely (e.g., mechanical valve needing Coumadin).\n22. Allergy or intolerance to DFX or rtPA.\n23. Active alcohol or drug use that impairs adherence to follow-up.\n24. Participation in another interventional trial. (Observational studies are allowed.\n25. Inability or unwillingness to provide informed consent. This includes patients who lack decision-making capacity (and have no available legally authorized representative) or those who decline participation.\n26. Not expected to survive to Day 365 or have DNR\u002FDNI status at time of screening.\n27. Any other condition that the investigator believes would pose a significant hazard or interfere with outcome assessments.\n28. Patients with confirmed aspiration, pneumonia, pulmonary edema, evident bilateral pulmonary infiltrates on CXR or CT scan prior to enrollment.\n29. Patients with significant respiratory disease such as chronic obstructive pulmonary disease, pulmonary fibrosis, or any use of chronic or intermittent inhaled O2 at home.\n30. The presence of 4 or more of the following risk modifiers for ARDS prior to enrollment:\n\n    1. Tachypnea (respiratory rate \\>30)\n    2. SpO2 \\\u003C95%\n    3. Obesity, defined as Body Mass Index (BMI) \\>30 d) Acidosis (pH \\\u003C7.35)\n\n    e. Hypoalbuminemia (albumin \\\u003C3.5 g\u002FdL) f. Concurrent use of chemotherapy\n31. Subjects who are taking prochlorperazine or are expected to undergo Gallium-67 imaging during the study period.\n32. Known severe hearing loss.\n33. Taking iron supplements containing ≥325 mg ferrous iron or prochlorperazine 34. Patients with heart failure taking \\>500 mg vitamin C daily",{"count":106,"type":22},240,[25,59],"This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared to standard medical care.\n\nThis trial represents the first investigation of a dual-modality approach in ICH, integrating mechanical clot evacuation with biochemical neuroprotection, with the goal of improving neurological outcomes.",[110,28],"Intracerebral Hemorrhage",[112,113,114,115,116,117,118],"deferoxamine","DFX","MIS","minimally invasive surgery","alteplase","ICH","Intracerebral hemorrhage","2025-10-06",{"date":121,"type":38},"2025-10-10",{"date":123,"type":22},"2026-03-01",{"date":125,"type":22},"2028-12-30",{"name":127,"class":45},"University of Illinois at Chicago",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":46},"100596176","placing-external-ventricular-drains-using-assistive-augmented-reality-or-image-based-localization-100596176","NCT07042048","Placing External Ventricular Drains Using Assistive Augmented Reality or Image-Based Localization","Placing External Ventricular Drains Using Assistive Augmented Reality or Image-Based Localization: A Randomized Controlled Clinical Trial (PEARL)","PEARL","Inclusion Criteria:\n\n* adult patient at time of screening\n* diagnosis of spontaneous ICH with IVH with severe TBI\n* Meet one or more of the following clinical or radiographic criteria:\n\nTissue swelling on imaging Dysmorphic ventricles on imaging Midline shift \\>2mm on imaging Mass effect on imaging Evans Index \\\u003C0.3 on imaging Glasgow Coma Scale 3-8\n\n* admitted to Cooper University Health\n* requires an EVD\n\nExclusion Criteria:\n\n* Other concomitant intracranial pathology (e.g., tumor, tumor-related edema\u002Fhemorrhage, congenital condition, etc.)\n* Concurrent participation in another research protocol for investigation of an experimental therapy\n* Known or suspected inability to adhere to study protocol or protocol requirements, as per the discretion of the investigator",{"count":137,"type":22},50,[84],"The goal of this clinical trial is to assess if EVD placement using augmented reality is non inferior to image-guidance systems for assistance in adult patients needing an EVD for spontaneous ICH with IVH or severe TBI. The main question it aims to answer is:\n\nCan EVDs be placed successfully with at least equal safety and efficacy using augmented reality devices in comparison to using standard image-guidance techniques?",[28,141,142],"IVH- Intraventricular Hemorrhage","TBI Traumatic Brain Injury",[144,145,146,117,147],"EVD","Augmented Reality","TBI","Image Guidance","2025-06-25",{"date":150,"type":38},"2025-06-27",{"date":152,"type":22},"2025-07-01",{"date":154,"type":22},"2026-03-31",{"name":156,"class":45},"The Cooper Health System",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":117,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100566389","epidemiology-of-intracerebral-hemorrhage-100566389","NCT06654544","Epidemiology of Intracerebral Hemorrhage","Prevalence and Clinical Features of Intracerebral Hemorrhage Among Stroke Patients Admitted to Assiut University Hospital","Inclusion Criteria:\n\n* both sex\n* Age ≥ 18\n* patients diagnosed with non traumatic hemorrhagic stroke on brain computed tomography scan\n\nExclusion Criteria:\n\n* presence of space occupying lesion visible on brain computed tomography scan\n* preceding brain trauma or post traumatic cerebral hemorrhagic stroke\n* presence of ischemic stroke\n* presence hemorrhagic transformation on top of acute ischemic stroke",{"count":165,"type":22},60,"OBSERVATIONAL","Exploring the risk factors and associations of intracerebral hemorrhage",[28],[170,171],"prevalence","ich","2024-10-21",{"date":174,"type":38},"2024-10-23",{"date":176,"type":22},"2024-11-30",{"date":178,"type":22},"2025-12-31",{"name":180,"class":45},"Assiut University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100553814","predictors-of-early-hematoma-expansion-in-patients-with-acute-intracerebral-hemorrhage-clinical-and-laboratory-study-100553814","NCT06490978","Predictors of Early Hematoma Expansion in Patients With Acute Intracerebral Hemorrhage (Clinical and Laboratory Study)","Inclusion Criteria:\n\n* patients having spontaneous ICH aged 18 years or older admitted to a stroke unit within 24 hours After symptom onset .\n\nExclusion Criteria:\n\n1- patient have secondary ICH (cerebral aneurysm, Moyamoya syndrome, arteriovenous malformation, tumor, trauma or hemorrhagic transformation from brain infarction); (2)patient have primary intraventricular hemorrhage (IVH); (3)patients with historical modified Rankin scale (mRS) score greater than 1 (4) patient refused to be enrolled.",{"count":21,"type":22},"This study aim to develop inflammatory score based on proper integration of several inflammatory markers and investigate whether it was associated with hematoma expansion and poor outcomes in patients with ICH .",[28],"2024-07-05",{"date":192,"type":38},"2024-07-08",{"date":194,"type":22},"2024-10-01",{"date":196,"type":22},"2025-12-01",{"name":180,"class":45}]